Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the month of May 2004. The registrant is a foreign private issuer based in South Melbourne, Victoria, Australia. The filing serves as an Initial Director's Interest Notice submitted to the Australian Securities Exchange (ASX) and furnished to the SEC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings rather than a financial performance report.
Material Changes
The material change disclosed is the appointment of Dr. Jonas Alsenas as a Director on March 25, 2004. Consequently, the company is reporting his initial relevant interests in the company's securities.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly adheres to the requirements of ASX Listing Rule 3.19A.1 and Section 205G of the Corporations Act regarding director interests.
Important Facts for Investors
- Director Appointment: Dr. Jonas Alsenas was appointed as a Director on March 25, 2004.
- Shareholding Disclosure: Dr. Alsenas holds a registered interest in 70,000 Ordinary Shares (equivalent to 7,000 ADRs).
- Contractual Interests: The filing indicates no disclosed interests in contracts under Part 3 of the notice.
- Financial Data: No financial performance data is included in this specific filing.